ReviewBlood2019
Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms.
Review in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Clinicopathological Features, Treatment Response, and Outcome of Rosai-Dorfman Disease in Two Children.Clinical case reports · 2026Article
- Histiocyte Society blueprint for non-Langerhans cell histiocytosis research: unraveling complex diseases through collaboration.Haematologica · 2025Review
- Systemic inflammation biomarkers can identify high tumor mutation burden in lung adenocarcinoma.BMC cancer · 2025Article
- Retrospective nationwide survey of pediatric RDD in Japan: a high prevalence of mutations in the kinase pathway genes.International journal of hematology · 2025Article
- Utilizing multi-omics analysis, a new signature has been identified and validated for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma, which is based on tumor mutation burden.Discover oncology · 2025Article
- Identification of immune suppressor candidates utilizing comparative transcriptional profiling in histiocytic sarcoma.Cancer immunology, immunotherapy : CII · 2025Article
- Rosai-Dorfman-Destombes disease in adults: a single center experience.Annals of hematology · 2024Article
- Favorable outcome of a histiocytic sarcoma patient treated with immune checkpoint inhibitor: a case report.Annals of medicine and surgery (2012) · 2023Article
- Multi-omic analysis in normal colon organoids highlights MSH4 as a novel marker of defective mismatch repair in Lynch syndrome and microsatellite instability.Cancer medicine · 2023Article
- Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?Journal of clinical medicine · 2023Review
- A case of recurrent refractory cervical primary histiocytic sarcoma treated with pembrolizumab.International cancer conference journal · 2022Article
- Prolonged remission with pembrolizumab and radiation therapy in a patient with multisystem Langerhans cell sarcoma.Haematologica · 2022Article
- PD-1/PD-L1 expression is frequent and correlated with lymphocyte density in Erdheim-Chester disease.Haematologica · 2022Article
- Primary splenic histiocytic sarcoma associated with hemophagocytic lymphohistiocytosis: A case report and review of literature of next-generation sequencing involving FLT3, NOTCH2, and KMT2A mutations.Cancer reports (Hoboken, N.J.) · 2022Review
- Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.Disease markers · 2022Article
- Immunotherapy in endometrial cancer: rationale, practice and perspectives.Biomarker research · 2021Review
- Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease.Haematologica · 2020Article
- Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.Expert review of hematology · 2019Review
- Apparent Lack ofFrontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.